Παρασκευή 2 Ιουνίου 2017

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies

S03057372.gif

Publication date: Available online 1 June 2017
Source:Cancer Treatment Reviews
Author(s): Jeong A Park, Nai-Kong V. Cheung
Immune checkpoint inhibitors (ICI) have shown great promise in a wide spectrum of adult solid and hematological malignancies, achieving objective tumor responses and prolonging survival. However, there is limited clinical success amongst pediatric patients. In this review, we summarize the current understanding of ICI and present an up-to-date overview of recent and ongoing clinical trials of ICI in pediatric malignancies. In addition, we will discuss immunologic and clinical difficulties in this young population, as well as future prospects for combination of ICI with other immune-based and conventional treatments.



http://ift.tt/2qNFp3q

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου